Clinical Trial Evaluating the Impact of an Intensive Rehabilitation Program Combined With Tendon Vibratory Stimulation on Functional Balance in Individuals With Charcot-Marie-Tooth Disease Type 1A

Recruiting now · Not applicable

Conditions studied: Charcot-Marie-Tooth Disease Type 1A

In brief

Charcot-Marie-Tooth (CMT) disease is caused by a genetic abnormality involving the PMP22 gene, resulting in demyelination of the peripheral nerves. Demyelination leads to sensorimotor impairment and causes progressive muscle weakness and tendon contractures, initially affecting the lower limbs. Consequently, individuals with CMT experience balance impairments and gait disturbances, including ankle instability, foot drop, and postural instability, which lead to frequent falls and reduced quality of life. Currently, there is no disease-modifying treatment for CMT. Several rehabilitation approaches have been proposed, including endurance training and muscle strengthening programs, to improve independence in activities of daily living. However, rehabilitation practices for individuals with CMT remain poorly standardized, and there is still a lack of clearly defined rehabilitation protocols, despite broad agreement among healthcare professionals regarding their potential benefits. More recently, noninvasive focal tendon vibration has been investigated in several neurological disorders to improve sensory function, balance, and motor performance. Previous studies suggest that mechanical vibratory stimulation applied to the quadriceps tendon may induce sustained improvements in postural control and lower-limb muscle strength. The present study aims to evaluate a rehabilitation program combined with tendon vibratory stimulation. The objective is to compare the effectiveness of a short-term (2-week), intensive multidisciplinary rehabilitation program focused on balance with different types of focal tendon vibration, in order to better address balance impairments and their associated complications in individuals with Charcot-Marie-Tooth disease.

Key facts

Study ID

NCT07726043

Run by

UGECAM PACA et Corse

People needed

30

Starts

2025-04-28

Expected to finish

2027-12-31

Last updated by the study team

2026-08-03

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Individuals with genetically confirmed Charcot-Marie-Tooth disease type 1A (CMT1A), characterized by PMP22 gene duplication on chromosome 17 (17p11.2).
• Age between 18 and 65 years.
• Overall Neuropathy Limitations Scale (ONLS) score between 2 and 3/7 for the lower limbs.
• Affiliation with a social security/health insurance system.
• Written informed consent voluntarily provided after receiving information regarding the study objectives, procedures, and potential risks.

You may not qualify if…

• Comorbidities causing peripheral neuropathy (e.g., diabetes, renal failure, medication-induced neuropathy).
• Balance or gait disorders due to another cause.
• Individuals without a permanent residence.
• Individuals deprived of liberty by judicial or administrative decision or under legal guardianship.
• Individuals unable to understand the study objectives and procedures or unable to provide informed consent.
• Individuals unable to complete all study procedures.
• Previous use of the Vibramoov device.
• Pregnant women or women planning to become pregnant during the study period.
• Concurrent participation in another research study.

Where it is running

• IUR Valmante Sud — Marseille, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.